Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC Probe
2023-503574-20-00Phase 2Authorised
- Sponsor
- Owlstone Medical
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of d5-ethyl-beta-d-glucuronide, sponsored by Owlstone Medical. Primary endpoint: Diagnostic accuracy of OWL-EVO1 Breath Biopsy test. Planned start Nov 2023; status: authorised.
02
Drugs
d5-ethyl-beta-d-glucuronide
Beyond the preview
Go deeper on 2023-503574-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503574-20-00.